上海盟科药业股份有限公司 2023 年年度股东大会会议资料 证券代码：688373 证券简称：盟科药业 上海盟科药业股份有限公司 2023 年年度股东大会 会议资料 二 O 二四年四月 | 2023 年年度股东大会会议须知 | | 2 | | --- | --- | --- | | 2023 | 年年度股东大会会议议程 | 4 | | 议案一 | | 6 | | 关于《公司 | 2023 年年度报告及其摘要》的议案 | 6 | | 议案二 | | 7 | | 关于《公司 | 2023 年度财务决算报告》的议案 | 7 | | 议案三 | | 13 | | 关于《公司 | 年度财务预算报告》的议案 2024 | 13 | | 议案四 | | 16 | | 关于《公司 | 2023 年度董事会工作报告》的议案 | 16 | | 议案五 | | 26 | | 关于《公司 | 2023 年度监事会工作报告》的议案 | 26 | | 议案六 | | 32 | | 关于《公司 | 2023 年度利润分配方案》的议案 | 32 | | 议案七 | | 33 | | 关于审议公司董事 | 年年度薪酬奖金及 年薪酬方案的议案 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% in the next six months [18][33]. Core Insights - The company's revenue for 2023 reached 90.78 million yuan, representing a growth rate of 88.31% year-on-year. However, the net profit attributable to the parent company was -421.12 million yuan, reflecting a significant decline of 91.16% [9][33]. - The primary product, 康替唑胺, is expected to see substantial sales growth, with projected revenue of 149.78 million yuan in 2024, 262.12 million yuan in 2025, and 471.81 million yuan in 2026, corresponding to growth rates of 64%, 74%, and 80% respectively [36][33]. - The gross margin for 2023 was reported at 81.6%, showing stability despite a slight decrease of 0.1 percentage points year-on-year [18]. Financial Summary - The total share capital is 655 million shares, with a market capitalization of 3.6 billion yuan [2]. - The company's total assets amount to 1.169 billion yuan, with a net asset value per share of 1.27 yuan [2][33]. - The earnings per share (EPS) for the forecasted years are projected to be -0.64 yuan in 2024, -0.90 yuan in 2025, and -0.76 yuan in 2026 [33][36]. Revenue Forecast - The revenue forecast for 康替唑胺 is as follows: 2023A: 91 million yuan, 2024E: 150 million yuan, 2025E: 262 million yuan, and 2026E: 472 million yuan, with corresponding year-on-year growth rates [36][33]. Clinical Development - The company is actively advancing its clinical pipeline, with several ongoing clinical trials for 康替唑胺 and related products, including trials for pediatric applications and treatment for diabetic foot infections [34][33].

证券简称：盟科药业 证券代码：688373 上海盟科药业股份有限公司 投资者关系活动记录表 R特定对象调研 £分析师会议 投资者关系活动 £媒体采访 £业绩说明会 类别 □新闻发布会 □现场参观 □路演活动 □其他 形式 £现场 £网上 R电话会议 中金公司、国金证券、西南证券、申万宏源证券、东吴证券、天风证 券、华兴证券、东北证券自营、峰境基金、阳光资产、华泰资管、中 国人寿资产管理有限公司、上海国投、中邮基金、华宝基金、中天国 参与单位名称 富证券、观合资产、平安证券资管、沣谊投资、峰境基金、齐熙投 资、优益增投资、盛熙基金、青榕资产、深研汇、上海行知创业投资 有限公司、财通资管 时间 2024年3月27日、2024年3月28日 地点 上海市浦东新区爱迪生路53号 上市公司接待人 公司管理层 员姓名 投资者关系活动 1、 MRX-4国际多中心临床试验目前进度如何？ 主要内容介绍 答： 注射用MRX-4和康替唑胺片序贯用于治疗糖尿病足感染的全 球Ⅲ期临床试验国内首家中心已于2023年7月启动。截至2023年 年底，注射用MRX-4序贯康替唑胺片治疗糖尿病足感染的Ⅲ期临床 试验已获准在中国、美国、法国、西班牙 ...

Investment Rating - The investment rating for the company is "Buy" [7][10]. Core Views - The commercialization potential of the drug "康替唑胺" continues to be realized, with steady progress in the research and development pipeline [8][10]. - The company reported a total revenue of 90.77 million yuan for 2023, representing a year-on-year growth of 88.31%, while the net profit attributable to the parent company was -421 million yuan, compared to -220 million yuan in the previous year [7][10]. - The company is actively expanding its academic promotion and distribution network, with over 450 hospitals prescribing 康替唑胺 by the end of 2023 [8]. Financial Summary - For 2023, the company achieved total revenue of 90.77 million yuan, with a year-on-year growth rate of 88.31% [12]. - The net profit attributable to the parent company for 2023 was -421 million yuan, with projections for 2024 and 2025 being -414 million yuan and -312 million yuan, respectively [12][14]. - The gross margin for 2023 was 81.6%, with expectations of increasing to 83.0% in 2024 [12][14]. Research and Development Pipeline - The company has one marketed product and four drugs in clinical stages, with significant investments in R&D totaling 345 million yuan in 2023, a 129.31% increase year-on-year [9]. - Key clinical trials include MRX-4 for diabetic foot infections and MRX-8, which completed Phase I trials in China in 2023 [9]. - The company is also developing innovative drugs targeting kidney diseases and tumors through peptide-drug conjugates (PDC) and antibody-drug conjugates (ADC) technologies [9].

Financial Performance - The company has not achieved profitability since its establishment, with a net profit attributable to the parent company of negative value due to high R&D expenditures[4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year, representing a 25% year-over-year growth[18]. - The net loss attributable to shareholders was CNY -421,124,452.65 in 2023, worsening from CNY -220,298,739.18 in 2022, with a basic earnings per share of -0.64 CNY[26][28]. - The company's total assets decreased by 21.96% to CNY 1,168,564,953.55 at the end of 2023, while net assets attributable to shareholders fell by 31.32% to CNY 834,003,192.78[27]. - The net cash flow from operating activities showed a net outflow of CNY -329,081,951.34, which is a deterioration compared to CNY -240,008,344.56 in 2022[25][27]. - The weighted average return on equity was -41.12% in 2023, compared to -29.52% in 2022, indicating a significant decline in profitability[26][28]. Research and Development (R&D) - The company is expanding its R&D and academic promotion teams to enhance its core competencies in the treatment of infectious diseases[4]. - Research and development (R&D) expenses amounted to CNY 34,486.18 million, representing 379.90% of operating revenue, an increase of 67.93 percentage points from the previous year[28]. - The company continues to maintain a high level of R&D investment to enhance its core competitiveness and expand its drug pipeline[28]. - The company has established R&D centers in China and the US, with an international core R&D team experienced in innovative drug development[37]. - The company has invested 100 million CNY in new technology for drug development, aiming to reduce time-to-market by 30%[24]. - The total R&D expenditure for the year reached ¥344,861,801.85, a significant increase of 129.31% compared to the previous year[188]. Product Development and Pipeline - The core product, Kangti Zuoan tablets, has been launched, while multiple other products are in clinical trials both domestically and internationally[4]. - New product development includes the launch of three innovative drugs, with expected market entry in Q3 2024[21]. - The company’s research pipeline includes one marketed drug, four drugs in clinical stages, and multiple drugs in preclinical research[37]. - The company is actively advancing multiple innovative drug candidates in critical clinical trial phases, contributing to increased R&D spending[28]. - The company is focused on developing innovative drugs for infectious diseases, leveraging its global intellectual property and competitive advantages[44]. - The company is developing MRX-8, a new generation of polymyxin antibiotics aimed at improving safety while retaining efficacy against multi-drug resistant Gram-negative bacterial infections[170]. Market Strategy and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[22]. - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 200 million CNY in revenue[23]. - The company plans to increase its sales force by 20% to enhance distribution channels and customer engagement[26]. - The company has established a self-operated commercialization team of approximately 100 people in China, focusing on core markets and hospitals to drive commercialization efforts[83]. - The company is actively participating in national medical insurance negotiations and hospital access initiatives to enhance product availability and meet clinical needs[85]. Clinical Trials and Regulatory Approvals - The FDA granted QIDP and Fast Track designations for contezolid tablets and MRX-4 for treating moderate to severe diabetic foot infections in September 2023[42]. - The clinical trial for the expansion of contezolid tablets to treat complex skin and soft tissue infections in children started in April 2023[42]. - The company has received regulatory approvals for multiple drugs, including MRX-4 and 康替唑胺, with several in Phase III clinical trials[183][184]. - The ongoing phase III clinical trial of MRX-4 has enrolled 119 patients across multiple countries, including China, the US, and several European and South American nations[72]. Antimicrobial Resistance and Public Health - The global issue of antimicrobial resistance is projected to cause 10 million deaths by 2050 if no action is taken, significantly impacting global health and economies[88]. - Antimicrobial resistance is expected to lead to a GDP decline of 2%-3.5% globally by 2050, resulting in a potential loss of up to $100 trillion[88]. - The company emphasizes the importance of developing new antimicrobial drugs to combat the growing issue of resistance, as highlighted by WHO[88]. - The company is committed to providing professional product support services to promote the rational and standardized use of its products[85]. Financial Management and Governance - The board approved a profit distribution plan for 2023 that includes no cash dividends, no stock bonuses, and no capital reserve transfers[6]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has received a standard unqualified audit report from PwC Zhong Tian[6]. - The company emphasizes that future plans and development strategies mentioned in the report do not constitute substantive commitments to investors[7].

中国国际金融股份有限公司 关于上海盟科药业股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司持续监管办法 （试行）》等有关法律、法规的规定，中国国际金融股份有限公司（以下称"保荐机构"） 作为上海盟科药业股份有限公司（以下简称"盟科药业"或"公司"）持续督导工作的 保荐机构，负责盟科药业上市后的持续督导工作，并出具 2023 年度持续督导跟踪报告， 本持续督导期间为 2023 年 1 月 1 日至 2023 年 12 月 31 日。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 针对具体的持续督导工作制定相应的工作计 | 保荐机构已建立健全并有效执行了持续督导 | | | | 制度，并制定了相应的工作计划。 | | | 划。 | | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与盟科药业签订《保荐协议》，该 协议明确了双方在持续督导 ...

中国国际金融股份有限公司 关于上海盟科药业股份有限公司 （一）保荐机构：中国国际金融股份有限公司 （二）保荐代表人：陶泽旻、张小勇 （三）现场检查时间：2023 年 3 月 13 日、2023 年 3 月 20 日 （四）现场检查人员：中金公司：陶泽旻 （五）现场检查内容：公司治理及内部控制、信息披露、独立性、与关联方的资 金往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经营状况以 及承诺履行情况等。 （六）现场检查手段：与公司董事、董事会秘书、财务总监、副总经理李峙乐进 行访谈；查看上市公司主要经营、管理场所；查阅并复印公司本持续督导期间召开的 历次董事会及专门委员会文件；查阅上市公司募集资金台账、募集资金使用凭证、募 集资金专户银行对账单等资料；查阅公司建立或更新的有关制度文件；查阅公司定期 报告、临时报告等信息披露文件；了解本持续督导期间内公司关联交易、对外担保和 重大对外投资的相关情况。 二、现场检查的具体事项及意见 2023 年持续督导工作现场检查报告 根据《上海证券交易所科创板股票上市规则》等有关法律、法规的规定，中国国 际金融股份有限公司（以下简称"中金公司"）作为正在履行上海盟 ...

目录 CONTENTS | 01 | 环境、社会和公司治理 | | | --- | --- | --- | | | （ESG）管理体系 | | | 1.1 | ESG 管理 | 12 | | 1.2 | 利益相关方沟通 | 13 | | 1.3 | 实质性议题分析 | 14 | | 02 | 稳健合规运营， 夯实治理根基 | | | --- | --- | --- | | 2.1 | 公司治理 | 15 | | 2.2 | 商业道德 | 18 | | 2.3 | 风险管理与内部控制 | 20 | 2.4 数据安全与隐私保护 23 | 03 | 创新做良药， 共建健康未来 | | --- | --- | | 3.1 | 研发创新 | | 3.2 | 坚守研发伦理 | 3.3 知识产权管理 30 | 报告编制说明 | 04 | | --- | --- | | 关于盟科药业 | 06 | | 盟科药业 2023 年度 | 11 | | ESG 实践亮点 | | | ESG 数据绩效表 | 61 | | 对标索引表 | 67 | 04 以良药求良效， 打造优质产品 | 4.1 | 全流程药品质量管理 | 32 | | ...

上海盟科药业股份有限公司 2023 年度财务报表及审计报告 上海盟科药业股份有限公司 2023 年度财务报表及审计报告 | | 页码 | | --- | --- | | 审计报告 | 1 - 6 | | 2023 年度财务报表 | | | 合并资产负债表 | 1 - 2 | | 公司资产负债表 | 3 - 4 | | 合并利润表 | 5 | | 公司利润表 | e | | 合并现金流量表 | 7 | | 公司现金流量表 | 8 | | 合并股东权益变动表 | 9 | | 公司股东权益变动表 | 10 | | 财务报表附注 | 11 - 94 | | 补充资料 | 1 - 2 | 普华永道 审计报告 普华永道中天审字(2024)第 10130 号 (第一页,共六页) 上海盟科药业股份有限公司全体股东: 一、审计意见 (一) 我们审计的内容 我们审计了上海盟科药业股份有限公司(以下简称"盟科药业")的财务报表, 包括 2023年 12月 31日的合并及公司资产负债表,2023 年度的合并及公司利润表、 合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附注。 (二) 我们的意见 我们认为,后附的财务报表在 ...

内部控制审计报告 普华永道中天特审字(2024)第 1136 号 (第一页,共二页) 上海盟科药业股份有限公司全体股东: 上海盟科药业股份有限公司 2023 年度内部控制审计报告 普华永道 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况 的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 据内部控制审计结果推测未来内部控制的有效性具有一定风险。 普华永道中天会计师事务所(特殊普通合伙) 中国上海市黄浦区湖滨路202号领展企业广场2座普华永道中心11楼 邮编200021 总机:+86 (21) 2323 8888, 传真:+86 (21) 2323 8800, www.pwccn.com 普华永道 普华永道中天特审字(2024)第 1136 号 (第二页，共二页) 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审 计了上海盟科药业股份有限公司(以下简称"盟科药业")2023年12月31日的 财务报告内部控制的有效性。 一、 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制评价 指引》的规定,建立健全和有效实施内部控制,并评价其有 ...